| Literature DB >> 35683504 |
Julia Herrero Huertas1, Marta García Clemente2, Beatriz Díaz Molina3, José Luis Lambert Rodríguez3, Marta Íscar Urrutia2.
Abstract
The cardiopulmonary exercise (CPET) test is an essential tool to determine the severity, prognosis, and need for invasive treatments in heart failure with reduced ejection fraction (HFrEF) but disregards the exercise modality. The present study aimed at analyzing the differences between treadmill and cycle-ergometer exercises. This was a prospective study, involving 65 patients with HfrEF who performed treadmill exercise followed by cycle-ergometer exercise 72 h later. We enrolled 65 patients, aged 58 ± 9 years, with an ejection fraction of 29 ± 9%. Peak VO2 was 20% greater (95% CI: 18-21%; p < 0.000) on the treadmill, and the ventilatory efficiency estimated by the VE/VCO2 slope (32 ± 8 vs. 34 ± 9; p < 0.05). The ventilatory response was greater on the treadmill: maximum ventilation (55 ± 16 vs. 46 ± 11 L/min; p < 0.000) and ventilatory reserve at the maximum effort (28 ± 17 vs. 41 ± 15%; p < 0.000). These values led to a change in the functional class of 23 (51%) patients and ventilatory class of 28 (47%) patients. Differences in the main parameters, including peak VO2 and VE/VCO2, impact prognostic scales and possible advanced treatments; therefore, the results should be interpreted in accordance with the exercise modality.Entities:
Keywords: VE/VCO2 slope; VO2; cardiopulmonary exercise tests; cycle ergometer; heart failure with reduced ejection fraction; prognostic scales; treadmill
Year: 2022 PMID: 35683504 PMCID: PMC9181537 DOI: 10.3390/jcm11113122
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Baseline characteristics of the included patients (n = 65).
| Mean (SD)/No (%) | |
|---|---|
| Age (years) | 57.8 ± 9.3 |
| Sex (male) | 49 (75%) |
| Body mass index (kg/m2) | 29.2 ± 4.4 |
| Comorbidity Atrial fibrillation COPD Mild Moderate Severe Very severe | |
| Functional class NYHA class I NYHA class II NYHA class III NYHA class IV | |
| Cause of HFrEF Ischemic Idiopathic Hereditary Other | |
| LVEF (%) | 29.5 ± 8.6 |
| Laboratory values Hemoglobin (g/dL) Creatinine (mg/dL) Glomerular filtration rate (mL/min/1.73 m2) | |
| Spirometry (mL/% theoretical) FEV1 FVC FEV1/FVC ratio | |
| Chronic treatment Beta-blocker ACE-I ARB Mineralocorticoid receptor antagonist Angiotensin receptor-neprilysin inhibitor Loop diuretic Thiazides Ivabradine Digoxin Amiodarone | |
| Implantable cardioverter defibrillator Single chamber Cardiac resynchronization therapy | 34 (52%) |
COPD: chronic obstructive pulmonary disease; NYHA: New York Heart Association; HFrEF: heart failure with reduced left ventricular ejection fraction; LVEF: left ventricular ejection fraction; FEV1: maximum expiratory volume in the first second; FVC: forced vital capacity; ACE-I: angiotensin converting enzyme inhibitor; ARB: angiotensin AT1-receptor blocker.
Cardiopulmonary exercise testing parameters.
| CPET Variable | Treadmill | Cycle Ergometer | |
|---|---|---|---|
|
| 10.5 ± 2.7 | 10.2 ± 3.1 | NS |
|
| 93.8% | 76.9% | |
|
| 1.04 ± 0.05 | 1.03 ± 0.06 | NS |
|
| 69.6 ± 10.9 | 68.8 ± 11.0 | NS |
|
| 117.3 ± 15.7 | 107.5 ± 15.2 | |
|
| 22.4 ± 12.8 | 16.4 ± 8.8 | |
|
| 123.3 ± 21.6 | 125.3 ± 21.8 | NS |
|
| 158.7 ± 33.5 | 161.4 ± 30.9 | NS |
|
| 75.8 ± 10.8 | 78.9 ± 12.2 | |
|
| 81.5 ± 16.6 | 87.4 ± 16.2 | |
|
| 97.0 ± 1.3 | 97.2 ± 1.2 | NS |
|
| 96.4 ± 1.8 | 97.2 ± 1.4 | |
|
| 412.7 ± 162.2 | 416.6 ± 166.1 | NS |
|
| 1734.9 ± 549.9 | 1390.5 ± 427.0 | |
|
| 21.0 ± 5.1 | 16.9 ± 4.1 | |
|
| 1612.5 ± 382.5 | 1274.0 ± 361.8 | |
|
| 1587.7 ± 376.2 | 1259.0± 354.3 | |
|
| 14.6 ± 3.6 | 12.5 ± 3.3 | |
|
| 32.2 ± 7.9 | 33.9 ± 8.8 | |
|
| 54.7 ± 16.3 | 45.8 ± 11.4 | |
|
| 30.5 ± 5.6 | 27.3 ± 5.0 | |
|
| 35.6 ± 4.9 | 37.0 ± 5.5 | |
|
| 36.3 ± 5.0 | 37.4 ± 5.4 | |
|
| 32.0 ± 4.4 | 32.8 ± 4.9 | NS |
|
| 36.2 ± 4.2 | 36.1 ± 4.5 | NS |
|
| 3.8 ± 4.0 | 2.3 ± 4.7 | |
|
| 28.4 ± 17.1 | 41.1 ± 15.2 | |
|
| 29.6 | 36.5 | NS |
|
| 5.4 ± 2.4 | 3.7 ± 2.3 | |
|
| 3.8 ± 3.1 | 4.8 ± 2.4 |
CPET: Cardiopulmonary exercise test; VT: ventilatory threshold; RQ: respiratory quotient; HR: heart rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; VO2: oxygen consumption; VCO2: CO2 production; VE: ventilation; RR: respiratory rate; EqO2: oxygen equivalent; EqCO2: carbon dioxide equivalent; PETCO2: partial pressure end-tidal carbon dioxide; ΔPETCO2: PETCO2 increase from start of test to VT; BR: breathing reserve; NS: not significant.
VO2 variation during CPET.
| Treadmill | Cycle Ergometer | ||
|---|---|---|---|
| VO2 at rest | 412.7 ± 162.2 | 416.6 ± 166.1 | NS |
| VT VO2 | 1612.5 ± 382.5 | 1274.0 ± 361.8 | <0.000 |
| Peak VO2 | 1734.9 ± 549.9 | 1390.5 ± 427.0 | <0.000 |
Figure 1VO2 variation during CPET.
Figure 2Boxplot of cardiovascular variables and VO2 on the treadmill and cycle ergometer. (A) Peak VO2 (mL/min), (B) peak VO2/kg (mL/min/kg), (C) VO2/HR at VT (mL/bpm), (D) maximum HR (bpm), (E) HRR-1 (bpm), (F) systolic and diastolic BP at the maximum exercise (mmHg). VO2: oxygen consumption; HR: heart rate; HRR-1: HR recovery index; BP: blood pressure; NS: not significant.
Figure 3Boxplot of respiratory variables on the treadmill and cycle ergometer. (A) VE/VCO2 Slope, (B) maximum RR (rpm), (C) maximum VE (L/min), (D) VT Eq O2, (E) VT Eq CO2, (F) BR at maximum effort (%), (G) VT PET CO2 (mmHg). RR: respiratory rate; VE: ventilation; VT: ventilatory threshold; EqO2: oxygen equivalent; EqCO2: carbon dioxide equivalent; BR: breathing reserve; PETCO2: partial pressure end-tidal carbon dioxide; NS: not significant.
Figure 4(A) Analysis of the Weber functional class as a function of peak VO2/kg and ergometer. (B) Ventilatory class according to VE/VCO2 slope and ergometer.